CA3107120A1 - Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers - Google Patents

Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers Download PDF

Info

Publication number
CA3107120A1
CA3107120A1 CA3107120A CA3107120A CA3107120A1 CA 3107120 A1 CA3107120 A1 CA 3107120A1 CA 3107120 A CA3107120 A CA 3107120A CA 3107120 A CA3107120 A CA 3107120A CA 3107120 A1 CA3107120 A1 CA 3107120A1
Authority
CA
Canada
Prior art keywords
halo
alkyl
cancer
alkoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3107120A
Other languages
English (en)
French (fr)
Inventor
Mark Esposito
Yibin Kang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Publication of CA3107120A1 publication Critical patent/CA3107120A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3107120A 2018-07-31 2019-07-31 Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers Pending CA3107120A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862712434P 2018-07-31 2018-07-31
US62/712,434 2018-07-31
PCT/US2019/044278 WO2020028461A1 (en) 2018-07-31 2019-07-31 Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers

Publications (1)

Publication Number Publication Date
CA3107120A1 true CA3107120A1 (en) 2020-02-06

Family

ID=67734803

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3107120A Pending CA3107120A1 (en) 2018-07-31 2019-07-31 Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers

Country Status (8)

Country Link
US (2) US12162855B2 (https=)
EP (1) EP3830079A1 (https=)
JP (1) JP7613743B2 (https=)
CN (1) CN112638881B (https=)
AU (1) AU2019315444B2 (https=)
CA (1) CA3107120A1 (https=)
IL (1) IL280395B2 (https=)
WO (1) WO2020028461A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638881B (zh) 2018-07-31 2025-01-07 普林斯顿大学托管委员会 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
CA3168533A1 (en) * 2020-01-24 2021-07-29 The Trustees Of Princeton University Heterocyclic compounds and uses thereof
GB202019475D0 (en) 2020-12-10 2021-01-27 Cancer Research Tech Ltd Therapeutic compounds and their use
KR102925139B1 (ko) 2021-04-22 2026-02-10 카요테라 인코포레이티드 헤테로시클릭 화합물 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60126270A (ja) * 1983-12-14 1985-07-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
JPS61145162A (ja) * 1984-12-19 1986-07-02 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
DE3701277A1 (de) 1987-01-17 1988-07-28 Boehringer Mannheim Gmbh Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel
JPH01319453A (ja) * 1988-06-22 1989-12-25 Wakamoto Pharmaceut Co Ltd 新規ベンゾキノン誘導体
MXPA05012086A (es) 2003-05-12 2006-02-22 Pfizer Prod Inc Inhibidores de benzamida del receptor p2x7.
CN102225926A (zh) * 2003-11-07 2011-10-26 诺华疫苗和诊断公司 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
US7875624B2 (en) * 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
JP2006349902A (ja) * 2005-06-15 2006-12-28 Fujifilm Holdings Corp 黒白熱現像感光材料
EP2021502A4 (en) * 2006-05-09 2010-08-25 Mas Metabolic Analytical Servi GENES AND ATYPICAL MARKERS IN TYPE 2 DIABETES AND OBESITY
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
KR102319882B1 (ko) * 2014-02-19 2021-11-03 아비브 테라퓨틱스, 인크. 암의 치료를 위한 폴리사이클릭 아미드와 결합하는 미토콘드리아 알데히드 탈수소효소 2 (aldh2) 및 그의 용도
WO2015173169A1 (en) 2014-05-12 2015-11-19 Fondazione Istituto Italiano Di Tecnologia Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments
RU2743074C2 (ru) 2014-08-01 2021-02-15 Нуэволюшон А/С Соединения, активные по отношению к бромодоменам
CN112638881B (zh) 2018-07-31 2025-01-07 普林斯顿大学托管委员会 用于治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
CA3168533A1 (en) 2020-01-24 2021-07-29 The Trustees Of Princeton University Heterocyclic compounds and uses thereof
GB202019475D0 (en) 2020-12-10 2021-01-27 Cancer Research Tech Ltd Therapeutic compounds and their use
KR102925139B1 (ko) 2021-04-22 2026-02-10 카요테라 인코포레이티드 헤테로시클릭 화합물 및 이의 용도

Also Published As

Publication number Publication date
AU2019315444B2 (en) 2024-10-31
IL280395B2 (en) 2025-04-01
WO2020028461A1 (en) 2020-02-06
JP7613743B2 (ja) 2025-01-15
CN112638881B (zh) 2025-01-07
US20210155602A1 (en) 2021-05-27
EP3830079A1 (en) 2021-06-09
US12162855B2 (en) 2024-12-10
CN112638881A (zh) 2021-04-09
JP2021532158A (ja) 2021-11-25
AU2019315444A1 (en) 2021-02-11
IL280395A (en) 2021-03-01
US20250129046A1 (en) 2025-04-24
IL280395B1 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
US20250129046A1 (en) Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
US9926290B2 (en) Inhibitors of INV(16) leukemia
US20160159731A1 (en) Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof
Li et al. Novel pyrrolopyridone bromodomain and extra-terminal motif (BET) inhibitors effective in endocrine-resistant ER+ breast cancer with acquired resistance to fulvestrant and palbociclib
US20130116277A1 (en) Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
Wei et al. Discovery of SILA-123 as a highly potent FLT3 inhibitor for the treatment of acute myeloid leukemia with various FLT3 mutations
Sharma et al. First-in-class dual EZH2-HSP90 inhibitor eliciting striking antiglioblastoma activity in vitro and in vivo
WO2014039820A1 (en) Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
KR20250119621A (ko) Dna 폴리머라제 세타 억제제로서의 티아디아졸릴 유도체 및 그의 용도
Shi et al. Discovery of propionic acid derivatives with a 5-THIQ core as potent and orally bioavailable Keap1–Nrf2 protein–protein interaction inhibitors for acute kidney injury
JP2022538767A (ja) アセチルＣｏＡシンテターゼ２（ＡＣＳＳ２）阻害剤およびそれを使用する方法
Frey et al. Discovery of potent azetidine-benzoxazole MerTK inhibitors with in vivo target engagement
WO2023039662A1 (en) Phenanthridinium derivatives as ppm1a inhibitors and uses thereof
US11459295B2 (en) 2-beta-naphthyl-acetic acid analogs as AKR1C3 inhibitors and methods of using same
CN107141287B (zh) 2-亚胺-5-酮基-2,5-二氢-1-h-二吡啶并嘧啶类化合物
JP7445609B2 (ja) Ｅｐａｃ阻害剤としてのチエノ［２，３－ｂ］ピリジン誘導体及びその医薬用途
JP2022526844A (ja) 筋肉量及び酸化的代謝を増加させるための組成物及び方法
US20240174649A1 (en) Cullin-ring e3 ubiquitin ligase 4 inhibitor compounds and methods of their use
HK40049062A (en) Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
HK40049062B (zh) 用於治疗转移性和化疗耐受性癌症的四氢喹啉衍生物
US12570661B2 (en) Isoform-specific aldehyde dehydrogenase inhibitors
WO2016007993A1 (en) Benzene sulfonamide-based inhibitors of sphingosine kinase
Han et al. Discovery of the thieno [2, 3-b][1, 4] thiazin-2 (3H)-one STING inhibitors
Zhang et al. Zhijian Li2, 4, Huiran Qiu1, 4, Wenxia Lu1, 4, Namin Duan2, 4, Shule Fan1, Rui Zhou2, Xiangzhi Li1
Zhu Novel reactive oxygen species activated scaffold from mechanism to application

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240724

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240724

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240730

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240730

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241223

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250217

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250217

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250506

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250728

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250728

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250730

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251128

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260112

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260112